Navigation Links
China Medical Technologies Reports Second Fiscal Quarter Financial Results
Date:11/17/2010

year-over-year increase of not less than 49.5%.
  • Target non-GAAP diluted earnings per ADS* is expected to be not less than RMB10.69 (US$1.60), representing a year-over-year increase of not less than 49.9%.

  • The above targets are based on the Company's current views on the operating and market conditions, which are subject to change.

    *One American Depositary Share ("ADS") = 10 ordinary shares

    See "Non-GAAP Measure Disclosures" below, where the impact of certain items on reported results is discussed.

    "We are pleased to see the commencement of contribution from sales of HPV-DNA chips which are expected to become another main revenue stream and an important growth driver in addition to our FISH business during the next few years. We have received strong interest in our SPR equipment from many of our top tier hospital customers and significant purchase orders on our chips from hospitals which have used our chips for their patients on a regular basis. We expect substantial growth on sales of our chips in upcoming quarters. In addition, our FISH business continued its growth momentum and our ECLIA business has resumed year-over-year growth," commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company.

    2Q FY2010 Unaudited Financial ResultsThe Company reported revenues of RMB201.8 million (US$30.2 million) for 2Q FY2010, representing a 21.5% increase from the corresponding period of FY2009.

    The Company's revenues are currently generated from two segments, molecular diagnostic systems and immunodiagnostic systems. The molecular diagnostic system segment includes FISH products and SPR products while the immunodiagnostic system segment consists of ECLIA products.  

    Molecular diagnostic system sales for 2Q FY2010 were RMB118.3 million (US$17.7 million), representing a 32.6% increase from the corresponding period of
    '/>"/>

    SOURCE China Medical Technologies, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
    2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
    3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
    4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
    5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
    6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
    7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
    8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
    9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
    10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
    11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
    (Date:7/10/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), a ... entered into an agreement with Merck KGaA, Darmstadt, ... in the United States and ... KGaA,s biopharmaceutical division on the development and commercialization of ... Ventana,s proprietary diagnostic assays. In alignment with Merck KGaA,s ...
    (Date:7/10/2014)... 2014 Decision Resources Group finds that over ... Food and Drug Administration,s (FDA) approval of Vifor Fresenius ... was approved by the FDA in November 2013 for ... patients on dialysis. Other key findings from ... 2014 : , ...
    Breaking Medicine Technology:ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
    (Date:7/13/2014)... irrigation systems are mainly utilized for agriculture in order ... maintain soil quality. The application of micro irrigation systems ... generator for manufacturers in future. The trend of utilizing ... to the adoption of micro irrigation techniques for agriculture, ... for micro irrigation systems, as they reduce the overall ...
    (Date:7/13/2014)... MarketsandMarkets recently conducted a study on ... 3D rendering; Layout and Animation; Image Reconstruction]: Global ... which analyzes and studies the major market drivers, ... Eastern Europe, Middle East and Africa, Asia-Pacific and ... landscape of the 3D imaging market, providing an ...
    (Date:7/13/2014)... York (PRWEB) July 13, 2014 The ... http://www.transvaginalmeshlawsuithelp.com/ ) filed against Johnson & Johnson’s ... bellwether trial, which is expected to get underway next ... in the U.S. District Court, Southern District of West ... be held on August 7, 2014 at 3:00 p.m. ...
    (Date:7/13/2014)... Texas (PRWEB) July 13, 2014 Epidemiologists ... aGVHD in the 6MM, from 8,062 diagnosed incident cases ... at an Annual Growth Rate (AGR) of 4.35%, during ... the highest number of diagnosed incident cases of aGVHD ... Spain will have the lowest number of diagnosed incident ...
    (Date:7/13/2014)... Columbus, OH (PRWEB) July 13, 2014 ... by Wright & Schulte LLC to provide consumers with ... can sometimes accompany use of the blood-thinning medication, as ... lawsuits pending in courts around the country. The ... anyone who may have suffered from life-threatening internal bleeding ...
    Breaking Medicine News(10 mins):Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 2Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 3Health News:Ethicon Vaginal Mesh Lawsuits Move Forward, As Federal Court Schedules Pretrial Conference for Second Bellwether Case, Bernstein Liebhard LLP Reports 4Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4
    ... stigma is powerful, pervasive and destructive," said Marlene Schwartz, a ... reactions to two prom photos.// , One showed a ... woman. The other was the same photo altered to show ... ,The volunteers took a quick look at one or ...
    ... may be much more likely to have asthma and a nighttime ... from Australia.// ,Doctors often use night cough as a guide ... the August issue of Chest, suggest it may be appropriate to ... ,"Night cough is often taken as a sign of the onset ...
    ... for cancer complain of feeling weak //and tried, and ... symptoms. A new study suggests that may not be ... with worse prognosis after radiotherapy, the doctors assumed the ... of the therapy, as well., ,Not so, report ...
    ... New research shows the same drugs you take to ... ,Researchers from the University of Pittsburgh followed more than ... than seven years. Results of the study show more ... cholesterol-lowering drugs developed breast cancer, while 2.1 percent of ...
    ... proved exercise reduces the risk of breast cancer, and now ... may lower a woman’s risk of developing breast carcinoma in ... into invasive breast cancer if left untreated. ,Researchers from ... 35 and 64 years old. More than 550 participants had ...
    ... Lung cancer is by far the biggest cancer killer around the ... survey researchers found that 38 percent of 626 patients they ... 61 percent of the black and 29 percent of the white ... air would cause it to spread., Most of the patients were ...
    Cached Medicine News:Health News:False beliefs could cost cancer patients their lives 2
    ... Discovery 90SE Ultracentrifuge offers ... discover more. All the ... top-of-the-line performance, powerful functionality, ... use, all built into ...
    ... centrifuge continues to raise the standard for ... 1,048,000 x g performance and our new ... sample sizes from 0.2 ml to 8.3 ... direct drive, very quiet operation, rotor imbalance ...
    ... and environmental safety are the ... K Ultracentrifuge from Beckman Coulter. ... centrifugation technology, the LE-80 K ... provide advanced capability for your ...
    ... Capable of generating 694,000 ... to 90,000 rpm, Beckman Coulter's ... to perform more separations in ... model operates with a broad ...
    Medicine Products: